Lifang Lv

698 total citations
19 papers, 564 citations indexed

About

Lifang Lv is a scholar working on Molecular Biology, Cancer Research and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lifang Lv has authored 19 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Cancer Research and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lifang Lv's work include Cardiac Fibrosis and Remodeling (5 papers), Diabetes Treatment and Management (4 papers) and Diabetes Management and Research (3 papers). Lifang Lv is often cited by papers focused on Cardiac Fibrosis and Remodeling (5 papers), Diabetes Treatment and Management (4 papers) and Diabetes Management and Research (3 papers). Lifang Lv collaborates with scholars based in China, Switzerland and Kenya. Lifang Lv's co-authors include Hongli Shan, Yuhong Zhou, Xuelian Li, Haihai Liang, Rui Yang, Xiaoguang Zhao, Lanlan Chen, Yingqi Liu, Yingnan Li and Chaoqian Xu and has published in prestigious journals such as Biochemical Pharmacology, European Journal of Pharmacology and Journal of Cellular Physiology.

In The Last Decade

Lifang Lv

19 papers receiving 558 citations

Peers

Lifang Lv

CCM

EDM

SURGE

Jingjing Wu China

Christine Heinzle Austria

Ahmed Lawan United States

Nermin Ali Japan

Hongjiao Xiang China

Christine L. Webb United States

Alain Vérine France

Wenquan Hu China

Moua Yang United States

Michael G. Borland United States

Jingjing Wu China

Lifang Lv

309 ×0.9

112 ×0.5

35 ×0.4

CCM

63 ×0.8

EDM

45 ×0.6

SURGE

Citations per year, relative to Lifang Lv Lifang Lv (= 1×) peers Jingjing Wu

Countries citing papers authored by Lifang Lv

Since Specialization

Citations

This map shows the geographic impact of Lifang Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifang Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifang Lv more than expected).

Fields of papers citing papers by Lifang Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lifang Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifang Lv. The network helps show where Lifang Lv may publish in the future.

Co-authorship network of co-authors of Lifang Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Lifang Lv. A scholar is included among the top collaborators of Lifang Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lifang Lv. Lifang Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Bi, Fangfang, Lifang Lv, Hua Tian, et al.. (2024). ITFG2, an immune-modulatory protein, targets ATP 5b to maintain mitochondrial function in myocardial infarction. Biochemical Pharmacology. 226. 116338–116338. 2 indexed citations

Wang, Yujing, Yue Li, Yao Liu, et al.. (2023). Neuroepithelial cell-transforming 1 promotes cardiac fibrosis via the Wnt/β-catenin signaling pathway. iScience. 26(10). 107888–107888. 7 indexed citations

Wu, Yun, Cui Chen, Jingrui Li, et al.. (2022). Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ. European Journal of Pharmacology. 923. 174892–174892. 12 indexed citations

Li, Chao, Lifang Lv, Shuangshuang Chen, et al.. (2022). Endocytosis of Peptidase Inhibitor SerpinE2 promotes Myocardial Fibrosis through activating ERK1/2 and β-catenin Signaling Pathways. International Journal of Biological Sciences. 18(16). 6008–6019. 17 indexed citations

Lv, Lifang, Nan Zheng, Lijia Zhang, et al.. (2020). Metformin ameliorates cardiac conduction delay by regulating microRNA-1 in mice. European Journal of Pharmacology. 881. 173131–173131. 12 indexed citations

Zhang, Lijia, Lifang Lv, Nan Zheng, et al.. (2020). Suppression of Sox4 protects against myocardial ischemic injury by reduction of cardiac apoptosis in mice. Journal of Cellular Physiology. 236(2). 1094–1104. 11 indexed citations

Liang, Haihai, Xiaomin Su, Qiuxia Wu, et al.. (2019). LncRNA 2810403D21Rik/Mirf promotes ischemic myocardial injury by regulating autophagy through targeting Mir26a. Autophagy. 16(6). 1077–1091. 96 indexed citations

Qiao, Shanshan, et al.. (2018). Relationship between social support and mental health among nurses in China:a Meta-analysis. The Journal of practical nursing. 34(32). 2548–2553. 1 indexed citations

Yu, Mengxue, Yingzhun Chen, Xuelian Li, et al.. (2018). YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. Cell Death and Disease. 9(5). 464–464. 73 indexed citations

10.

Lv, Lifang, Tianyu Li, Xuelian Li, et al.. (2017). The lncRNA Plscr4 Controls Cardiac Hypertrophy by Regulating miR-214. Molecular Therapy — Nucleic Acids. 10. 387–397. 99 indexed citations

11.

Jia, Haiyan, Quanzhong Li, & Lifang Lv. (2016). HDAC5 Inhibits Hepatic Lipogenic Genes Expression by Attenuating the Transcriptional Activity of Liver X Receptor. Cellular Physiology and Biochemistry. 39(4). 1561–1567. 12 indexed citations

12.

Zhou, Yuhong, Lin Deng, Dandan Zhao, et al.. (2016). MicroRNA‐503 promotes angiotensin II‐induced cardiac fibrosis by targeting Apelin‐13. Journal of Cellular and Molecular Medicine. 20(3). 495–505. 70 indexed citations

13.

Su, Yong, et al.. (2015). Association of gene polymorphisms in ABO blood group chromosomal regions and menstrual disorders. Experimental and Therapeutic Medicine. 9(6). 2325–2330. 5 indexed citations

14.

Li, Xuelian, Dandan Zhao, Haihai Liang, et al.. (2015). Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling. Frontiers of Medicine. 9(4). 444–456. 15 indexed citations

15.

Wang, Qiong, Yong Su, & Lifang Lv. (2015). A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α-glucosidase inhibitor. International Journal of Diabetes in Developing Countries. 36(4). 420–425. 1 indexed citations

16.

Zhou, Yuhong, Yun Wu, Lanlan Chen, et al.. (2014). The alkaloid matrine of the root of Sophora flavescens prevents arrhythmogenic effect of ouabain. Phytomedicine. 21(7). 931–935. 43 indexed citations

17.

Su, Yong, Yali Su, Lifang Lv, et al.. (2014). A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Experimental and Therapeutic Medicine. 7(4). 799–803. 9 indexed citations

18.

Su, Yong, Yali Su, Lifang Lv, et al.. (2014). Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus. Experimental and Therapeutic Medicine. 7(6). 1752–1756. 3 indexed citations

19.

Wang, Chun, Lifang Lv, Dawei Chen, et al.. (2011). Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clinical Endocrinology. 76(6). 810–815. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact